论文部分内容阅读
本试验系对天津试制协作组自大肠杆菌1:357菌体内分离得之治疗白血病新药L-门冬酰胺酶进行实验动物肿瘤鉴定,结果对瓦克氏癌肉瘤256有较明显的抑制作用,对淋巴肉瘤,白血病615,艾氏腹水瘤,肉瘤180抑制作用不明显。对瓦克氏癌肉瘤256提高用药剂量抑制率明显增加,制品纯度与抑制率之间的关系不明显。本品在水溶状态下不稳定,宜在用时溶解。长期使用可能使抑制率下降。以100—1000单位/公斤对大鼠无毒性反应,对小鼠400—800单位/公斤,则可致肝脏出血,小肠出现溃烂段。
This experiment was conducted on the tumor animal identification of L-asparaginase, a new leukemia drug that was isolated from the E. coli 1:357 strain of E.coli in Tianjin Trial Production Collaboration Group. The result was a significant inhibitory effect on 256 S. cerevisiae sarcoma. Lymphosarcoma, leukemia 615, Ehrlich ascites tumor, and sarcoma 180 had no obvious inhibitory effect. The inhibitory rate of 256-enhanced drug administration in WACKER’s carcinosarcoma increased significantly, and the relationship between product purity and inhibition rate was not significant. This product is unstable in water-soluble conditions and should be dissolved when in use. Long-term use may reduce the inhibition rate. With 100-1000 units/kg non-toxic to rats, 400-800 units/kg mice, can cause liver bleeding, ulceration of the small intestine.